I am sure this new CEO will take on the Eisai battle. He needs the revenue to come in to grow this company and I sure hope he is ready for a fight. At least hold them accountable... I don't want to wait for the CVOT to be completed to see Eisai turn on the jets.... Would like to see them get real involved after Belviq XR is approved.
be posted, keeps disappearing.. Easy to find on Linked In.
A new CEO and temporary financial officer is good news as well. We at least have someone to take the helm.... He can't be much worse then Jack Lief was...
You posted that on My-Gale. Started with this:
Thank you itsyou!
Background: Folate Binding Protein (FBP) (aka Folate Receptor-α)
Is this what you are talking about?
link please, thought this data was out last year.
The science is good, the researchers are good but Craig Audet and many others are a wasted payroll. How do we remove them or call them out?
Research suggests diabetes drug acts differently from previous theories
A Mayo Clinic study suggests laboratory findings do not tell the whole story of how the diabetes drug metformin works to limit the level of glucose in the blood. The researchers found that metformin does not limit the action of the hormone glucagon, specifically glucagon-stimulated glucose production from the liver. The article appears in the journal Cell Reports.
"In our clinical trial, metformin treatment appeared to trigger a compensatory increase of glucagon that may mitigate the ability of metformin to lower glucose production in prediabetic individuals and prevent the likelihood of hypoglycemia," explained K. Sreekumaran Nair, M.D., Ph.D., Mayo Clinic endocrinologist and senior author of the article.
Metformin's action is generally related to the release of glucose from the liver. The liver releases glucose when prodded by a pancreatic hormone called glucagon. Glucagon is released when blood glucose levels drop. Metformin is thought to limit the action of glucagon, the substances used to make it, or affect the level of enzymes used to make it.
Yet that's not what Dr. Nair and colleagues found in their double-blind study of nine prediabetic individuals.
The researchers found that for the six individuals with fasting (basal) glucagon levels of less than 150 picograms/milliliter, metformin treatment decreased the liver's production of glucose as expected. But for the three individuals with basal levels greater than 150 pg/mL, levels of glucose produced by the liver actually increased after metformin treatment.
This contradictory finding may be due to both the study design and participants. Unlike previous preclinical metformin research, this study used human participants and metformin at therapeutic doses. Studies in animal or cellular models have examined higher doses, or used drugs in the same class as metformin that are not approved for use in humans. .
You won't get an answer from this poster. He was at his mental limit when he cloned an id.
lowest reported in more than 4 years. Amazing shorts were able to cover while driving price down and tutes were also able to build a position. That is a very important tell, ignore the bashers, naysayers and the Debbie Downers, they are living in the past. You don't buy a stock based on past performance, you buy it based on its potential in the future. Future earnings, future discoveries, future drug candidates.
I don't short stocks but thank you anyway. I am a long-term investor when I say long-term I mean 3 to 6 years.
Warning Biotech Investors: FDA Advisory Panels' No Means No, Yes Means Maybe was a good article and should probably be read by investors here and ignore the bloggers, carnival barkers and shrills paid to spin this. Usually a No at the Advisory Committee means No, but in some rare occasions the FDA will go against them but that is rare...